MacroGenics amends 8-K to update pro forma financials for CDMO asset sale to Bora Pharmaceuticals
MGNX•Cash, costs and gain on sale
Deal proceeds of $119.6 million net were received from Bora Pharmaceuticals, with $8.8 million of transaction costs.
Pro forma cash rose by $110.81 million to $177.32 million as of March 31, 2026.
Estimated gain on derecognition of the sold assets totaled $91.71 million, reflected as a reduction in accumulated deficit.
Impact on continuing operations
Contract manufacturing revenue and related costs were removed from continuing operations, reflecting the exit from the manufacturing business.
Amended filing updates pro forma financials
MacroGenics filed an amended Form 8-K to restate unaudited pro forma financials tied to its June 30, 2026 CDMO asset sale.
